ArticleOphthalmology and therapy2026
Intraoperative Modified Peripheral Panretinal Photocoagulation in Proliferative Diabetic Retinopathy.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThis study aimed to compare the outcomes of intraoperative conventional panretinal photocoagulation (CPRP) with the modified peripheral panretinal photocoagulation (PPRP) technique in pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR).
methodsSixty-three eyes of 56 patients with PDR were retrospectively studied. Patients with very severe proliferation were excluded in this study. Twenty-six patients (30 eyes) received CPRP and 30 patients (33 eyes) received modified PPRP in PPV. Preoperative and postoperative ophthalmologic examinations were performed. Best corrected visual acuity (BCVA) was performed at baseline and 3 months after surgery. Central macular thickness (CMT) was measured at 1 week and 3 months after surgery. Postoperative inflammation was examined at 1 day and 3 months after surgery. Other postoperative complications were also analyzed at 3 months after surgery.
resultsOf all the included eyes, 24 eyes (38.1%) were diagnosed with neovascularization elsewhere (NVE) and/or neovascularization of the disc (NVD) and 39 eyes (61.9%) were diagnosed with tractional retinal detachment (TRD) preoperatively. The number of laser spots in the CPRP group ranged from 858 to 2245, with an average of 1232 (1048,1369) spots. The number of laser spots in the PPRP group ranged from 394 to 992, with an average of 673 (579, 798) spots. The mean logMAR BCVA before surgery was 1.71 ± 0.57 in the CPRP group and 1.57 ± 0.64 in the modified PPRP group, with no statistical difference between the two groups (P = 0.476). The mean logMAR BCVA was 1.15 ± 0.74 in the CPRP group and 0.77 ± 0.54 in the PPRP group at 3 months after surgery, showing that the PPRP group had more visual acuity improvement than the CPRP group (P = 0.037). There was a significant correlation between BCVA and the number of laser spots (P = 0.006). The difference of CMT between the two groups was statistically significant at 1 week after surgery (P = 0.02), but not at 3 months after surgery (P = 0.587). The postoperative inflammation in the CPRP group was significantly more severe than that in the PPRP group at the first day after surgery (P = 0.002). The postoperative inflammation in both groups was significantly reduced 3 months after surgery, with no statistical difference (P = 0.593). There was a significant correlation between the degree of inflammation and the number of laser spots at the first day after surgery (P = 0.016). There was no significant difference in the incidence of other complications between the two groups.
conclusionThe modified PPRP technique was used during PPV in patients with PDR in this study, resulting in better BCVA, decreased CMT, and reduced early postoperative inflammation without increasing the incidence of adverse events in PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.